Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Jump Financial LLC

Jump Financial LLC trimmed its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 82.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,760 shares of the company's stock after selling 50,793 shares during the period. Jump Financial LLC's holdings in Twist Bioscience were worth $500,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Thrivent Financial for Lutherans raised its position in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after purchasing an additional 532,040 shares during the period. Jennison Associates LLC raised its position in Twist Bioscience by 80.2% during the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock valued at $31,636,000 after purchasing an additional 302,884 shares during the period. American Century Companies Inc. raised its position in Twist Bioscience by 63.5% during the fourth quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock valued at $35,148,000 after purchasing an additional 293,751 shares during the period. ARK Investment Management LLC raised its position in Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after purchasing an additional 237,772 shares during the period. Finally, Vanguard Group Inc. raised its position in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after purchasing an additional 189,791 shares during the period.

Twist Bioscience Stock Down 3.4 %

NASDAQ TWST traded down $1.36 during midday trading on Wednesday, hitting $38.32. 922,873 shares of the company traded hands, compared to its average volume of 980,372. The company's 50-day simple moving average is $39.34 and its 200-day simple moving average is $44.18. Twist Bioscience Co. has a 52 week low of $30.32 and a 52 week high of $60.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The company has a market cap of $2.29 billion, a PE ratio of -11.34 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company's revenue was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.75) earnings per share. As a group, equities research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

TWST has been the topic of a number of recent research reports. Guggenheim set a $50.00 price objective on Twist Bioscience in a research report on Friday, March 28th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Barclays reduced their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $52.80.

Insider Activity

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Patrick John Finn sold 2,058 shares of the firm's stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total value of $82,299.42. Following the completion of the transaction, the chief operating officer now owns 265,460 shares in the company, valued at $10,615,745.40. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,432 shares of company stock worth $1,038,170 in the last quarter. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.